^
    12ms
    Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast). (ASCO 2023)
    In this proof-of-concept study, O did not show clinically nor statistically significant antitumor activity in pretreated aTNBC pts with BRCA1/2-meth. Clinical trial information: NCT03205761. >*7 pts had ≥3 CT lines.
    Clinical • PARP Biomarker • BRCA Biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PMS2 (PMS1 protein homolog 2) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 promoter methylation
    |
    Tempus xE • Tempus xF Assay
    |
    Lynparza (olaparib)
    over1year
    A cohort study evaluating the clinical, environmental and genetic profiles of men with early-onset, aggressive prostate cancer. (ASCO-GU 2023)
    In this cohort study we identified an unexpectedly high frequency of family histories that were positive for cancer (85%), and specifically PC (46%). However, rates of germline mutations associated with hereditary PC were similar to previous studies (15%), suggesting the possibility that other novel hereditary mutations driving increased PC risk may be present. Increased rates of somatic mutations in BRAF (35%) were also seen.
    Clinical
    |
    BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • ACTA2 (Actin Alpha 2 Smooth Muscle)
    |
    TP53 mutation • BRAF mutation
    |
    Tempus xE
    almost2years
    Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort. (PubMed, BMC Cancer)
    We predict HRD-positive patients across many cancer types and believe both HRD models may generalize to other mechanisms of HRD outside of BRCA loss. HRD-RNA complements DNA-based HRD detection methods, especially for indications with low prevalence of BRCA alterations.
    Real-world evidence • Journal • BRCA Biomarker • Pan tumor
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • PALB2 (Partner and localizer of BRCA2) • CDK12 (Cyclin dependent kinase 12) • BRCA (Breast cancer early onset) • RAD51B (RAD51 Paralog B) • RAD51C (RAD51 paralog C)
    |
    HRD • PALB2 mutation • RAD51 mutation
    |
    Tempus xT Assay • Tempus xE • Tempus xO assay
    over2years
    Tempus Announces Six Abstracts Accepted For Poster Presentation at the 2021 San Antonio Breast Cancer Symposium (Businesswire)
    "Tempus...today announced six abstracts accepted for poster sessions at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place December 7 - 10. The presented findings highlight the unique insights that Tempus’ data and smart diagnostics generate to advance breast cancer research."
    Preclinical
    |
    Tempus xT Assay • Tempus xE • Tempus xO assay
    |
    KB-0742